A randomised study comparing cisplatin 120 mg intravenously with cyclophosphamide 2 g intravenously, each drug being given every month for six months followed by a low dose regimen for a further six months in responding patients, was carried out in 86 patients with advanced epithelial ovarian carcinoma (FIGO stages III and IV).
Introduction
Alkylating agents have been used for many years in the treatment of advanced carcinoma of the ovary with reported objective response rates of 35-65 o,/ and 5-15 I" of all patients maintaining a response after two years.' Cisplatin (cis-dichlorodiammine platinum (11) ), introduced more recently, has been used mainly in combination with other agents-for example, cyclophosphamide and doxorubicin (Adriamycin).' 3It has also been claimed to be effective as a single agent in patients resistant to alkylating agents,4 but it has rarely been used as a single agent in patients previously untreated with chemotherapy. 6 No randomised trial has been reported comparing cisplatin as a single agent with an alkylating agent such as cyclophosphamide used at high dose.
The North Thames Cooperative Group, inaugurated in 1980, is composed of medical practitioners with an interest in gynaecological cancer. In 1980 a study was begun to determine whether cisplatin administered as a single agent is more effective than high dose cyclophosphamide for advanced epithelial carcinoma of the ovary, FIGO (International Federation of Gynaecology and Obstetrics) stage III or IV. An additional aim was to assess whether patients who had failed to respond to one drug could be salvaged by the other.
Materials and methods
Patients with stage III or IV carcinoma of the ovary and who were less than 75 years of age were eligible. Epithelial carcinomas of the following histological types were included in the trial: serous, mucinous, endometrioid, mesonephroid, mixed epithelial, undifferentiated; all other tumours, including borderline malignancy, were excluded. In all cases the histological findings were reviewed by two pathologists (Dr M Anderson Dr J Beilby).
All patients were randomised after surgery-but before review of the histological findings by the pathology panel-to receive either cisplatin or cyclophosphamide. Before 
Results
A total of 117 patients with stage III or IV epithelial ovarian carcinoma were entered into the trial between April 1980 and September 1982. Twenty five patients were excluded after randomisation when review indicated inappropriate histological findings. A further six patients were also excluded because they were found after randomisation to be less than stage III or died before receiving any chemotherapy. This left 86 patients for analysis, 37 of whom drew cyclophosphamide and 49 cisplatin. Table I gives the characteristics of the patients. Sixty five patients were stage III and 21 stage IV. All surviving patients remained in the trial for a minimum of two years. Their ages ranged from 39 to 75 years (median of 55). Optimal surgery (hysterectomy, bilateral salpingo-oophorectomy, infracolic omentectomy) was carried out in 42 of the 86 patients. Of the variables recorded-age, stage of disease, and surgery-only optimal surgery was found to be unevenly allocated between the two treatment groups, 26 (53°) of patients who had drawn cisplatin having received optimal surgery compared with 16 (431") of patients who had drawn cyclophosphamide. In addition, 11 out of 12 grade 1 tumours were in the platinum treated group, but analysis of this apparent disparity showed it to be not significant. Patients treated with cisplatin survived significantly longer than those treated with cyclophosphamide (p = 0 009) (fig 2) . The duration of response, both complete and partial (defined as 501" reduction in tumour size as estimated by clinical examination, ultrasound, etc), was also significantly longer in the cisplatin arm (p = 0006) (fig 3) . This effect remained when the curves were adjusted for optimal surgery, though significance was less (p = 004), reflecting the imbalance in numbers receiving optimal and suboptimal surgery between the two groups. The equivalent curves for complete clinical response (fig 4) did not reach statistical significance but showed the same trend in favour of cisplatin.
Patients who received optimal surgery before chemotherapy survived significantly longer than those given suboptimal surgery (p = 0 006) (fig 5) , and this effect was independent of treatment group (adjusted p value= 0-009). Figure 6 shows a similar comparison, but for complete responders only, no significant difference being apparent. 
Discussion
In view of the lack of studies com advanced ovarian cancer we decided domised controlled study the individual used chemotherapeutic agents before en chemotherapy. An increase in clinical observed using combination chemoth single alkylating agent, but an increase i] been shown." 12 The single exception melphalan with hexa-CAF (hexameth phamide, methotrexate, and fluorourac not confirmed by others comparing higl phosphamide with hexa-CAF. '4 The optimal dose and frequency of for cytotoxic agents in ovarian cancer is cisplatin high dose therapy has been fe sponse rate."-A high response rate w been found in patients resistant to and weekly cisplatin is now being used z untreated patients with advanced ovari were well differentiated in we opted for 120 mg given every four weeks because we had cystadenocarcinomas. Sixfound that higher doses caused peripheral neuropathy in some s, 10 endometrioid, and the patients. For a true comparison between two drugs it is important ial, none of which were well that they are given by the same route, and thus both cisplatin and eatment and survival in this cyclophosphamide were given intravenously.
The aim of chemotherapy is to eliminate all residual disease ly associated with the state left after surgery. While clinical examination and routine ininical response were able to vestigations such as chest radiography will detect gross recur-,ontinued to work throughrence and further information is obtained when ultrasound and ling patients, however, the CT are added, for deposits of less than 1 cm or residual microie main toxic effect of both scopic disease second look surgery with biopsy is the most as particularly severe with accurate method of detection and should be used in assessing he patients receiving cycloclinical response in prospective randomised trials. ients receiving cisplatin as surgically than cyclophosphamide. The value of surgical ie toxicity included one case complete response in predicting prolonged survival was conia but transfusion was not firmed in our series but the numbers were small.
The importance of cytoreductive surgery for long term survival has been emphasised. '8 20 In this study survival was greater in patients who had had a hysterectomy, bilateral salpingooophorectomy, and infracolic omentectomy. The extent of initial surgery did not significantly affect duration of response in patients who achieved a complete clinical response, although the numbers were small and follow up was not long enough to compare proportions of long term survivors.
The importance of verifying the diagnosis of ovarian epithelial carcinoma when conducting trials was confirmed in this trial, as 210/0 of cases had to be withdrawn on pathological grounds, the most frequent problems being of "unknown origin," primary tumour in the bowel, and borderline malignancy. The imporOptimal surgery tance of pathological type and grade of tumour has been studied n-29) differentiated tumours responded badly compared with well differentiated ones. In analysing our own series grade of tumour was not found to be a relevant factor. nse after optimal and subAt present prolongation of survival is difficult to obtain in most patients with advanced ovarian cancer, and when these patients are treated the quality of their lives must be taken into account. In this series the quality of life of patients who achieved complete clinical response was good. It was notable that several of the younger patients returned to full time work while receiving paring single agents for treatment, although psychological problems in continuing treat-I to examine in a ranment were present in most patients after six months. Patients 1 value of two commonly with bulk disease not responding to chemotherapy found the nbarking on combination side effects of treatment an additional burden to their remaining response rate has been life. This factor must be taken into consideration before conerapy compared with a tinuing with cytotoxic treatment in non-responders. n patient survival has not
In conclusion, our study shows the importance of comparing was a study comparing single agents before embarking on trials comparing a single agent iylmelamine, cyclophoswith combination chemotherapy. As cisplatin gave a longer disil).13 This difference was ease free survival than cyclophosphamide it would appear that h dose intravenous cyclocisplatin rather than an alkylating agent is the drug of choice both when a single agent is used in the treatment of advanced administration required ovarian carcinoma and when comparisons are to be made between unknown. In the case of combination therapy and a single drug. While a recent study22 )und to give a higher recomparing a combination regimen containing cisplatin (CHAP rith weekly cisplatin has 5) with hexa-CAF showed a longer median disease free survival previous chemotherapy, in the cisplatin group, it remains to be proved whether such a as induction treatment in combination is superior to cisplatin alone or whether it merely ian cancer. 16 In this trial adds increased toxicity and expense. The Tromso heart study: coffee consumption and serum lipid concentrations in men with hypercholesterolaemia: a randomised intervention study OLAV HELGE FORDE, SYNNPVE FONNEBO KNUTSEN, EGIL ARNESEN,
DAG STEINAR THELLE Abstract
In a 10 week trial to assess the effects of coffee consumption and coffee brewing methods on serum cholesterol concentrations 33 men with hypercholesterolaemia were randomly assigned to: continue with their usual coffee intake; stop drinking coffee altogether; or stop drinking coffee for five weeks, thereafter drinking either boiled or filter coffee. Cholesterol concentrations fell significantly in all subjects abstaining for the first five weeks compared with subjects not giving up and continued to fall in those abstaining for 10 weeks. Cholesterol concentrations rose Introduction Two recent reports have linked coffee consumption with serum cholesterol concentration.1 2 Findings in both studies were based on consumption of black, boiled coffee. The only other study of this relation in man of which we are aware confirms these findings.3 Here we report a study to assess the effect on blood lipid concentrations of: (1) abstention from coffee in men with hypercholesterolaemia and (2) brewing coffee in two different ways.
Subjects and methods
The participants originated from a multifactorial intervention study of 1373 men at high risk of heart disease, aged 35-54, initiated during
